Gladstone Institutional Advisory’s Xeris Biopharma Holdings XERS Stock Holding History

Gladstone Institutional Advisory’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,500	Closed	-$17.1K	–	720
2023 Q1	$17.1K	Hold	10,500	–	–	﹤0.01%	651
2022 Q4	$14K	Sell	10,500 -25,000	-70%	-$35.3K	﹤0.01%	640
2022 Q3	$55K	Hold	35,500	–	–	﹤0.01%	620
2022 Q2	$55K	Hold	35,500	–	–	﹤0.01%	635
2022 Q1	$91K	Hold	35,500	–	–	0.01%	680
2021 Q4	$104K	Sell	35,500 -18,000	-34%	-$38.9K	0.01%	580
2021 Q3	$131K	Buy	53,500 +5,000	+10%	+$14.5K	0.01%	516
2021 Q2	$197K	Hold	48,500	–	–	0.02%	486
2021 Q1	$219K	Sell	48,500 -3,000	-6%	-$16.2K	0.03%	371
2020 Q4	$253K	Buy	+51,500	New	+$258K	0.05%	256

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gladstone Institutional Advisory's XERS Position: Q2 2023 in Review

Gladstone Institutional Advisory sold out of Xeris Biopharma Holdings (XERS) in Q2 2023, closing a stake of 10,500 shares — an estimated $17.1K sold.

Gladstone Institutional Advisory first reported a position in XERS in Q4 2020 and held it in 10 quarters. The position peaked at $253K in Q4 2020. 103 funds tracked by Wall St. Rank hold XERS as of Q2 2023.

Gladstone Institutional Advisory reported no remaining Xeris Biopharma Holdings position as of Q2 2023 after selling out during the quarter.
Gladstone Institutional Advisory sold 10,500 Xeris Biopharma Holdings shares in Q2 2023, an estimated $17.1K.
Gladstone Institutional Advisory first reported a position in Xeris Biopharma Holdings in Q4 2020 and held it in 10 quarters.
Gladstone Institutional Advisory's Xeris Biopharma Holdings position peaked at $253K in Q4 2020.
103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2023.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2023, filed 10 Aug 2023.